41O Stock Overview
Operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Outlook Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$4.82 |
52 Week High | US$9.52 |
52 Week Low | US$4.44 |
Beta | 0.63 |
11 Month Change | -0.82% |
3 Month Change | -28.06% |
1 Year Change | -34.86% |
33 Year Change | -78.09% |
5 Year Change | -73.22% |
Change since IPO | -90.73% |
Recent News & Updates
Recent updates
Shareholder Returns
41O | DE Biotechs | DE Market | |
---|---|---|---|
7D | -5.5% | -0.7% | -0.02% |
1Y | -34.9% | -17.2% | 8.2% |
Return vs Industry: 41O underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 41O underperformed the German Market which returned 8.2% over the past year.
Price Volatility
41O volatility | |
---|---|
41O Average Weekly Movement | 9.0% |
Biotechs Industry Average Movement | 6.5% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.9% |
10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 41O's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 41O's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 24 | Russ Trenary | www.outlooktherapeutics.com |
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte.
Outlook Therapeutics, Inc. Fundamentals Summary
41O fundamental statistics | |
---|---|
Market cap | €114.26m |
Earnings (TTM) | -€90.32m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.3x
P/E RatioIs 41O overvalued?
See Fair Value and valuation analysisEarnings & Revenue
41O income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$34.18m |
Gross Profit | -US$34.18m |
Other Expenses | US$59.86m |
Earnings | -US$94.05m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -3.98 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -38.8% |
How did 41O perform over the long term?
See historical performance and comparison